LILRB1抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

LILRB1 (Leukocyte Immunoglobulin-Like Receptor B1), also known as CD85j or ILT2. is an inhibitory receptor predominantly expressed on immune cells, including monocytes, macrophages, dendritic cells, natural killer (NK) cells, and subsets of T and B cells. It belongs to the LILR family of transmembrane glycoproteins that regulate immune responses by interacting with MHC class I molecules. LILRB1 transmits inhibitory signals through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic domain, dampening cellular activation and effector functions to maintain immune homeostasis and prevent excessive inflammation.

In pathological contexts, LILRB1-mediated suppression is exploited by tumors and pathogens to evade immune surveillance. For example, many cancers overexpress MHC class I molecules to engage LILRB1 on cytotoxic T cells or NK cells, thereby inhibiting their anti-tumor activity. This mechanism has driven interest in developing LILRB1-blocking antibodies to counteract immune suppression in the tumor microenvironment. Such antibodies aim to restore effector cell function, potentially enhancing responses to immunotherapy. Conversely, agonistic LILRB1 antibodies are explored for treating autoimmune or inflammatory diseases by amplifying inhibitory signals.

Current research focuses on optimizing antibody specificity (e.g., distinguishing LILRB1 from homologous receptors like LILRB2) and evaluating combinatorial therapies with checkpoint inhibitors (e.g., anti-PD-1). Preclinical studies demonstrate promising results in models of solid tumors and hematologic malignancies, with several candidates advancing to early-phase clinical trials. Challenges include managing potential autoimmune side effects and understanding context-dependent receptor interactions.